



Correction: PKR Inhibition Prevents Neuroinflammation and Rescues Depressive-Like Behaviors Via BDNF/TrkB Signaling

Yue Hu¹ · Tahir Ali¹ · Shengnan Mou¹ · Qichao Gong¹ · Ruyan Gao¹ · Yanhua Luo¹ · Shupeng Li¹ · Li Ling² · Liangliang Hao³

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2026

Correction to: Journal of Neuroimmune Pharmacology
<https://doi.org/10.1007/s11481-025-10180-y>

In this article, Figs. 4B and 7B were identified as containing two inadvertent technical errors in the presentation of β -Actin loading controls, specifically:

- **Fig. 4B:** The β -Actin panel was inadvertently duplicated as the loading control for the NRF2, SOD2, and HO-1 panels in Supplementary Fig. 2.
- **Fig. 7B:** The β -Actin panel currently shown does not correspond to the original blot used in the densitometric analysis presented in the figure.

For completeness and transparency, the previous incorrect versions of Figs. 4B and 7B are displayed below:

The original article can be found online at <https://doi.org/10.1007/s11481-025-10180-y>.

✉ Shupeng Li
lisp@pku.edu.cn

✉ Li Ling
lingli2018@email.szu.edu.cn

✉ Liangliang Hao
haoliangliang@cdutcm.edu.cn

Yue Hu
2101111268@stu.pku.edu.cn

Tahir Ali
tali@bs.qau.edu.pk

Shengnan Mou
2001212630@stu.pku.edu.cn

Qichao Gong
gongqch@stu.pku.edu.cn


Ruyan Gao
gaoruyan@pku.edu.cn

Yanhua Luo
2001212649@stu.pku.edu.cn


- ¹ State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
- ² Department of Endocrinology, The 6th Affiliated Hospital of Shenzhen University Medical School, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518052, China
- ³ Hospital of Chengdu, University of Traditional Chinese Medicine, No.39 Shi-er-Qiao Road, Chengdu 610075, China

Fig. 4

A: C16 treatment reduced LPS-enhanced cytokines in the hippocampus



B: C16 reduced IKK β /NF- κ B/NLRP3 in the LPS-treated mice hippocampus



C: C16 treatment reduced LPS-enhanced IBA-1/GFAP level in the hippocampus






Fig. 7

A: K252a treatment attenuated C16 effect on TNF- α and TGF- β




B: K252a treatment attenuated C16 effect on NF- κ B and IKK β




Figures 4B and 7B should have appeared as shown below:

Fig. 4

A: C16 treatment reduced LPS-enhanced cytokines in the hippocampus



B: C16 reduced IKK β /NF- κ B/NLRP3 in the LPS-treated mice hippocampus



C: C16 treatment reduced LPS-enhanced IBA-1/GFAP level in the hippocampus






Fig. 7

A: K252a treatment attenuated C16 effect on TNF- α and TGF- β



B: K252a treatment attenuated C16 effect on NF- κ B and IKK β



The original article has been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.